A Dose Ranging Study of Modafinil for Methamphetamine Dependence

Status Active, not recruiting

Clinical Trial Summary

Patients treated for methamphetamine dependence have high rates of relapse, and no pharmacotherapy has yet been demonstrated to be efficacious. Modafinil (d, l-2-[(diphenylmethyl)sulfinyl]acetamide) is a novel wake- and vigilance-promoting agent that is chemically and pharmacologically dissimilar to CNS stimulants. It is well tolerated and has low abuse liability compared to CNS stimulants. Modafinil is FDA approved for a variety of sleep disorders, may relieve methamphetamine withdrawal symptoms, improves cognitive function, has been shown to reduce cocaine use in dependent users, and is safe when coadministered with intravenous methamphetamine. We will conduct a randomized dose ranging clinical trial of modafinil to establish its safety and efficacy as a pharmacotherapy for methamphetamine dependence.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00630097
Study type	Interventional
Source	California Pacific Medical Center Research Institute
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 2009
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00887367` - EtOH Interaction Study	Phase 1
Completed	`NCT01036061` - GSK618334 Repeat Dose Study	Phase 1
Completed	`NCT01189799` - Motivational Therapy for Substance Users With Depression	N/A
Completed	`NCT01381133` - Adolescent Outpatient and Continuing Care Study	Phase 3
Recruiting	`NCT04430257` - Pre-exposure Prophylaxis (PrEP) for Health	N/A
Completed	`NCT01128140` - Efficacy Trial of Warrior Check-Up	Phase 2
Completed	`NCT03767907` - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial	N/A
Recruiting	`NCT05833399` - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn	`NCT01515917` - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)	N/A
Completed	`NCT00208143` - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia	Phase 4
Withdrawn	`NCT03762798` - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone	N/A
Completed	`NCT03048552` - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3	N/A
Active, not recruiting	`NCT04768920` - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD)	N/A
Recruiting	`NCT05410561` - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients	N/A
Recruiting	`NCT05679284` - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn	`NCT00908206` - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics	Phase 1
Recruiting	`NCT05348317` - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders	N/A
Recruiting	`NCT01741415` - Distress Tolerance Treatment for Substance Users	Phase 2
Active, not recruiting	`NCT01621711` - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care	N/A
Active, not recruiting	`NCT00609089` - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction	Phase 1/Phase 2